Jade Ghosn

Summary

Country: France

Publications

  1. ncbi Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1
    Jade Ghosn
    APHP, Department of Internal Medicine, Bicetre University Hospital, Le Kremlin Bicetre, France
    J Med Virol 85:8-15. 2013
  2. ncbi Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial
    Jade Ghosn
    Department of Internal Medicine and Infectious Diseases, AP HP, Bicetre University Hospital, Le Kremlin Bicetre Cedex, France
    HIV Med 11:137-42. 2010
  3. ncbi Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort
    Jade Ghosn
    Universite Paris Descartes, EA MRT 3620, Virology Department, AP HP, Centre Hospitalier Universitaire Necker Enfants Malades, 149 rue de Sevres, 75015 Paris, France
    J Antimicrob Chemother 65:741-8. 2010
  4. ncbi Undetectable HIV-1 RNA load with the Cobas TaqMan v1.0 in a patient diagnosed at the time of primary HIV-1 infection
    Jade Ghosn
    Laboratoire de Virologie, Universite Paris Descartes, CHU Necker Enfants Malades, 149, rue de Sevres, 75015 Paris, France
    J Med Virol 82:1816-8. 2010
  5. ncbi Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine
    Jade Ghosn
    Laboratoire de Virologie, EA MRT 3620, Universite Rene Descartes Paris 5, CHU Necker Enfants Malades, Paris, France
    J Antimicrob Chemother 61:1344-7. 2008
  6. ncbi Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen
    Jade Ghosn
    Paris Descartes University, EA 3620, Necker University Hospital, Paris, France
    PLoS ONE 6:e24798. 2011
  7. ncbi Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy
    Jade Ghosn
    AP HP, Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:1542-4. 2008
  8. ncbi X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI
    Jade Ghosn
    Universite Paris Descartes, EA 3620, CHU Necker Enfants Malades, Paris, France
    PLoS ONE 6:e23301. 2011
  9. ncbi Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
    Jean Francois Delfraissy
    AP HP, Department of Internal Medicine and Infectious Diseases, Bicetre University Hospital, Le Kremlin Bicetre, France
    AIDS 22:385-93. 2008
  10. ncbi No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients
    Jade Ghosn
    Department of Infectious and Tropical Diseases, , Paris, France
    AIDS 19:1643-7. 2005

Detail Information

Publications57

  1. ncbi Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1
    Jade Ghosn
    APHP, Department of Internal Medicine, Bicetre University Hospital, Le Kremlin Bicetre, France
    J Med Virol 85:8-15. 2013
    ..2 hr. Tolerability of once-daily darunavir/r 800/100 mg was excellent. Optimally suppressed, treatment-experienced patients can switch safely from a twice-daily PI/r regimen to a once-daily darunavir/r 800/100 mg containing regimen...
  2. ncbi Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial
    Jade Ghosn
    Department of Internal Medicine and Infectious Diseases, AP HP, Bicetre University Hospital, Le Kremlin Bicetre Cedex, France
    HIV Med 11:137-42. 2010
    ..MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy with zidovudine/lamivudine and lopinavir/ritonavir in antiretroviral-naïve patients...
  3. ncbi Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort
    Jade Ghosn
    Universite Paris Descartes, EA MRT 3620, Virology Department, AP HP, Centre Hospitalier Universitaire Necker Enfants Malades, 149 rue de Sevres, 75015 Paris, France
    J Antimicrob Chemother 65:741-8. 2010
    ..To analyse immunovirological status during primary HIV-1 infection (PHI) according to contemporary clinical status and time since infection...
  4. ncbi Undetectable HIV-1 RNA load with the Cobas TaqMan v1.0 in a patient diagnosed at the time of primary HIV-1 infection
    Jade Ghosn
    Laboratoire de Virologie, Universite Paris Descartes, CHU Necker Enfants Malades, 149, rue de Sevres, 75015 Paris, France
    J Med Virol 82:1816-8. 2010
    ....
  5. ncbi Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine
    Jade Ghosn
    Laboratoire de Virologie, EA MRT 3620, Universite Rene Descartes Paris 5, CHU Necker Enfants Malades, Paris, France
    J Antimicrob Chemother 61:1344-7. 2008
    ..More than 80% of untreated HIV-infected men have detectable HIV-RNA in semen and such a strategy could favour local selection of resistant variants, given the poor penetration of most PIs in semen...
  6. ncbi Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen
    Jade Ghosn
    Paris Descartes University, EA 3620, Necker University Hospital, Paris, France
    PLoS ONE 6:e24798. 2011
    ..We show that pre-therapy mutations in gag cleavage site sequence were significantly associated with the virological outcome of a first-line LPV/r single drug regimen in the Monark trial...
  7. ncbi Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy
    Jade Ghosn
    AP HP, Department of Infectious Diseases, Pitie Salpetriere Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Antimicrob Agents Chemother 52:1542-4. 2008
    ..At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV...
  8. ncbi X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI
    Jade Ghosn
    Universite Paris Descartes, EA 3620, CHU Necker Enfants Malades, Paris, France
    PLoS ONE 6:e23301. 2011
    ..X4-tropic variants present at baseline were still exclusive (patients D and E) or dominant (at least one time point, patient C) far from PHI...
  9. ncbi Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
    Jean Francois Delfraissy
    AP HP, Department of Internal Medicine and Infectious Diseases, Bicetre University Hospital, Le Kremlin Bicetre, France
    AIDS 22:385-93. 2008
    ..Guidelines for the use of antiretroviral agents for HIV-1 infection recommend combining at least three agents. The toxicity, cost, and complexity of such regimens warrant the search for other options...
  10. ncbi No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients
    Jade Ghosn
    Department of Infectious and Tropical Diseases, , Paris, France
    AIDS 19:1643-7. 2005
    ....
  11. ncbi HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time
    Jade Ghosn
    Laboratoire de Virologie, CHU Necker Enfants Malades, Université René Descartes Paris, France
    AIDS 20:159-70. 2006
    ....
  12. ncbi Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + n
    Cathia Soulie
    Université Pierre et Marie Curie Paris, UMR S 943, INSERM, U943, Paris, France
    AIDS 23:1605-8. 2009
    ..The NNRTI + protease inhibitor strategy should not be recommended as an antiretroviral first-line regimen, particularly in patients with high viral load at baseline...
  13. ncbi Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study
    Stephanie Dominguez
    Département des Maladies Infectieuses et Tropicales INSERM U720, CHU Pitie Salpetriere, Paris, France
    J Med Virol 79:105-10. 2007
    ..This add-on pilot study supports the concept of double dose tenofovir to virologically overcome the decreased sensitivity of NRTI-resistant viruses. However, the safety of this regimen needs to be considered carefully...
  14. ncbi MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    AIDS 18:1299-304. 2004
    ..MIV-310 (alovudine), a nucleoside reverse transcriptase inhibitor, potently inhibits the replication of highly mutated strains of HIV in vitro. We examined the efficacy of MIV-310 in highly pretreated patients...
  15. ncbi Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone
    Philippe Flandre
    INSERM U 943, Paris, France
    Antivir Ther 14:93-7. 2009
    ..The objective of this study was to determine prognostic factors of VR in patients receiving LPV/r monotherapy...
  16. ncbi Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals
    Claudine Duvivier
    Department of Infectious Diseases, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 8:603-9. 2003
    ..To evaluate the efficacy and tolerability of indinavir/ritonavir (IDV/RTV) 400/100 mg twice daily in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive patients...
  17. ncbi Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial
    Véronique Avettand-Fenoel
    AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    J Antimicrob Chemother 65:1005-7. 2010
    ..To study the impact of protease inhibitor monotherapy on the HIV-1 blood reservoir in 72 antiretroviral-naive patients...
  18. ncbi Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
    Marc Wirden
    Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:644-7. 2004
    ....
  19. ncbi Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy
    Juliette Pavie
    Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Department of Infectious Diseases, University of Paris Diderot Paris 7, France
    J Antimicrob Chemother 66:2372-8. 2011
    ..Limited data are available on the use of unboosted atazanavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced HIV-infected patients...
  20. ncbi Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men
    Jade Ghosn
    Laboratoire de Virologie, EA MRT 3620 Université R Descartes, CHU Necker, Paris
    AIDS 18:447-57. 2004
    ..To study the genetic diversity of drug-resistant HIV strains present in blood and in semen, especially those archived in peripheral blood mononuclear cells (PBMC) and non-sperm cells (NSC)...
  21. ncbi HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART
    Cathia Soulie
    Department of Virology EA2387, Pitie Salpetriere Hospital, University Pierre et Marie Curie, Paris, France
    AIDS 21:2243-5. 2007
    ..This suggests that CCR5 antagonist activity should not be compromised in patients harbouring R5 viruses before starting HAART...
  22. ncbi Short communication: evidence of HIV type 1 complex and second generation recombinant strains among patients infected in 1997-2007 in France: ANRS CO06 PRIMO Cohort
    Julie Galimand
    Université Paris Descartes EA 3620, Paris, France
    AIDS Res Hum Retroviruses 26:645-51. 2010
    ....
  23. ncbi Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen
    Constance Delaugerre
    Virology Department, Saint Louis Hospital APHP, Paris, France
    AIDS 22:1809-13. 2008
    ..Limited data are available on resistance pattern emerging in patients failing DRV/r and on subsequent remaining protease inhibitor options...
  24. ncbi Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris F 75013, France
    J Antimicrob Chemother 62:797-808. 2008
    ..The aim of this study was to evaluate the impact on body fat of nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens compared with NRTI-containing therapy in HIV-1-infected antiretroviral (ARV)-naive patients...
  25. ncbi Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance
    Ana Canestri
    Department des Maladies Infectieuses, , Paris, France
    Antivir Ther 11:561-6. 2006
    ..CONCLUSION: In patients with HIV mutations conferring resistance to all antiretroviral drug classes, foscarnet markedly reduced plasma HIV load and improved immunological status...
  26. ncbi Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients
    Jade Ghosn
    Department of Infectious Diseases, Inserm EO214, , Paris, France
    AIDS 17:209-14. 2003
    ..Tolerability of RTV/IDV was excellent. CONCLUSION: RTV/IDV (100/400 mg bid) yields significantly higher IDV plasma Cmin and lower IDV Cmax values relative to the standard IDV regimen, thereby improving both tolerability and efficacy...
  27. ncbi Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients
    Jean Paul Viard
    Assistance Publique Hopitaux de Paris, Hôpital Necker Necker Enfants Malades, Universite Paris Descartes, France
    AIDS 23:1383-8. 2009
    ..To evaluate the efficacy of adding interleukin-2 (IL-2) to an optimized background treatment in HIV-1 patients with advanced failure...
  28. ncbi Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study
    Stephanie Dominguez
    AP HP, Département de Maladies Infectieuses et Tropicales, INSERM U720, CHU Pitie Salpetriere, Paris, France
    J Antimicrob Chemother 65:2445-9. 2010
    ..To compare plasma antiretroviral concentrations in HIV-HCV co-infected and in matched HIV mono-infected patients...
  29. ncbi Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection
    Sabrinel Sahali
    AP HP, Bicetre University Hospital, Department of Internal Medicine and Infectious Diseases, Paris Sud University, Le Kremlin Bicetre, France
    AIDS Rev 10:4-14. 2008
    ..The more frequent occurrence of low-level viremia, however, does not allow the widespread use of such a strategy outside of clinical studies at this time...
  30. ncbi Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy
    Constance Delaugerre
    University Paris Descartes, EA 3620, Virology Department, Necker Hospital AP HP, Paris, France
    Antimicrob Agents Chemother 53:2934-9. 2009
    ..The mutation L76V may be considered in further studies of lopinavir resistance...
  31. ncbi Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris, France
    AIDS 23:817-24. 2009
    ..To evaluate the change in bone mineral density (BMD) at specific sites in patients initiating antiretroviral therapy in a substudy of the ANRS 121 trial...
  32. ncbi High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study
    Pierre Frange
    EA 3620, AP HP, Laboratoire de Virologie, Hopital Necker Enfants Malades, Universite Paris Descartes, Paris, France
    J Antimicrob Chemother 64:135-41. 2009
    ....
  33. ncbi Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men
    Jade Ghosn
    AP HP, EA MRT 3620, Universite Paris Descartes, Department of Virology, Necker Hospital, Paris, France
    AIDS 22:658-61. 2008
    ..HCV serology and serum HCV RNA should be examined periodically in HIV-infected men who have sex with men engaging in high-risk sexual behaviours...
  34. ncbi Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, 75013 Paris, France
    Antimicrob Agents Chemother 50:2553-6. 2006
    ..L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz...
  35. ncbi Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men
    Jade Ghosn
    Laboratoire de Virologie, , France
    AIDS 18:1958-61. 2004
    ..These are worrying findings, because suboptimal semen drug concentrations may enhance the risk of sexually transmitted drug-resistant HIV variants...
  36. ncbi Recent HIV-1 infection contributes to the viral diffusion over the French territory with a recent increasing frequency
    Pierre Frange
    Universite Paris Descartes, Equipe d accueil 3620, Sorbonne Paris Cité, Paris, France
    PLoS ONE 7:e31695. 2012
    ..To analyse the contribution of primary human immunodeficiency virus type 1 (HIV-1) infection (PHI) to the French viral epidemic...
  37. ncbi Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study
    Laurence Morand-Joubert
    Laboratory of Virology, AP HP, CHU Saint Antoine, UPMC University Paris 06, INSERM U943, Paris, France
    J Med Virol 84:1710-8. 2012
    ..A 3-month short-course intensified treatment with ENF did not improve Week-24 virological response in treatment-experienced patients infected with HIV-1 harboring resistant viruses that were still susceptible to two antiretroviral drugs...
  38. ncbi Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study
    Jade Ghosn
    Department des Maladies Infectieuses, CHU Pitie Salpetriere, AP HP, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 10:543-50. 2005
    ..To assess the impact of nucleoside analogue reverse transcriptase inhibitor (NRTI) combination therapy on muscle and liver lactate metabolism in HIV-infected patients...
  39. ncbi Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
    Jade Ghosn
    Department of Internal Medicine and Infectious Diseases, Bicetre University Hospital, Le Kremlin Bicetre, France
    Antivir Ther 15:993-1002. 2010
    ..For patients unable to tolerate these regimens, alternative therapeutic approaches are needed...
  40. ncbi HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors
    Jade Ghosn
    Universite Paris Descartes, EA MRT 3620, Laboratoire de Virologie, AP HP, CHU Necker Enfants Malades, Paris, France
    AIDS Rev 11:165-73. 2009
    ..The first data on rilpivirine resistance are encouraging, but still too preliminary...
  41. ncbi Breast enlargement in an HIV-infected man on combined antiretroviral therapy: what if it was carcinoma?
    S Sahali
    AP HP, Department of Internal Medicine and Infectious Diseases, Bicetre Hospital, Le Kremlin Bicetre, France
    Int J STD AIDS 21:373-4. 2010
    ..Gynaecomastia was first considered to be related to efavirenz and/or didanosine. Although breast carcinoma is rare among HIV-infected men, it should be considered as a potential cause of breast enlargement...
  42. ncbi Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy
    Hassane Izzedine
    Department of Nephrology, La Pitie Salpetriere Hospital, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie Paris IV, 75013 Paris, France
    J Infect Dis 194:1481-91. 2006
    ..Tenofovir disoproxil fumarate (TDF) may induce renal proximal tubulopathy (rPT). There are no data on pharmacogenomic predictors of rPT in the genes encoding the multidrug-resistance protein (MRP) 2 and MRP4 transporters...
  43. ncbi [Sexual transmission of hepatitis C virus]
    Jade Ghosn
    Laboratoire de Virologie, Universite Rene Descartes Paris V, EA MRT 3620, CHU Necker Enfants Malades, Paris
    Presse Med 34:1034-8. 2005
    ..Sexual transmission of HCV may be enhanced by other concomitant sexually transmitted infections with genital erosive lesions or via traumatic sexual intercourse with abrasion of the genital mucosa...
  44. ncbi Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial
    Odile Launay
    Universite Paris Descartes, France
    J Infect Dis 204:124-34. 2011
    ..Human immunodeficiency virus (HIV)-infected patients have decreased immune response to vaccines. Few data are available about pandemic flu vaccination in this population...
  45. ncbi Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen
    Constance Delaugerre
    Virology Department, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
    AIDS 24:2391-5. 2010
    ..In vitro, integrase inhibitors reduce proviral DNA levels and rapidly increase 2-long-terminal repeat (LTR) circle levels. We examined the effect of raltegravir on the time course of HIV-1 DNA forms in patients with controlled viremia...
  46. ncbi Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person
    Frédéric Méchaï
    1 AP HP, Internal Medicine and Infectious Diseases Department, Bicetre University Hospital, Paris XI University, Le Kremin Bicêtre, France
    J Med Virol 80:9-10. 2008
    ..Post-exposure prophylaxis was well tolerated, with no increase in liver function tests. The health care worker remained HIV-negative after a 6-month follow-up...
  47. ncbi Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial
    Odile Launay
    Paris Descartes University, France
    JAMA 305:1432-40. 2011
    ..Alternative schedules more immunogenic than the standard hepatitis B vaccine regimen are needed in patients with human immunodeficiency virus 1 (HIV-1) infection...
  48. ncbi Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA
    Marc-Antoine Valantin
    Departement des Maladies Infectieuses et Tropicales, , , Paris, France
    AIDS 17:2471-7. 2003
    ..The efficacy, safety profile, and the simplicity of the injection schedule of PLA make this filling material a potentially attractive treatment...
  49. ncbi Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study
    Marguerite Guiguet
    INSERM, U, Paris, France
    AIDS 26:2345-50. 2012
    ..We aimed to determine the effectiveness of boosted protease inhibitor monotherapy (BPIMT) initiated as a maintenance strategy in routine care and identify predictive factors of failure...
  50. ncbi Nuclear bilateral Bell's palsy and ageusia associated with Mycoplasma pneumoniae pulmonary infection
    Salim Trad
    Departement des Maladies Infectieuses et Tropicales, CHU Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    J Med Microbiol 54:417-9. 2005
    ..pneumoniae post-infectious neurological manifestations...
  51. ncbi Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir
    Jade Ghosn
    Clin Infect Dis 41:1360-1. 2005
  52. ncbi Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level
    Marc Wirden
    J Acquir Immune Defic Syndr 36:876-8. 2004
  53. ncbi Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients
    Stephanie Dominguez
    Department of Infectious and Tropical Diseases INSERM U 720, CHU Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 20:1157-61. 2006
    ..Treatment of acute hepatitis C (HCV) in HIV-infected patients has been poorly addressed...
  54. ncbi Atypical toxoplasmic manifestation after discontinuation of maintenance therapy in a human immunodeficiency virus type 1-infected patient with immune recovery
    Jade Ghosn
    Departement des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Pitié Paris, France
    Clin Infect Dis 37:e112-4. 2003
    ..This atypical recurrence was more likely to be a reinfection than a reactivation, as attested by the genotypic analysis of the Toxoplasma gondii strain recovered from the patient...
  55. ncbi Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission
    Roland Tubiana
    AIDS 16:1083-4. 2002
  56. ncbi Liver fibrosis and antiretroviral therapy
    Jade Ghosn
    Clin Infect Dis 42:271-2. 2006
  57. ncbi HIV-2 infection and HIV-associated nephropathy
    Hassane Izzedine
    AIDS 20:949-50. 2006